Merck & Co., Inc. - Form 13F Information Table Summary
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Merck & Co., Inc. for the period ending March 31, 2026. The document details the company's holdings in equity securities as of the reporting date. It is important to note that this form reports investment positions and does not contain Merck's own operating financial results (revenue, profit, or cash flow).
Key Financial Metrics and Holdings
The filing lists 14 equity positions, primarily in biotechnology and pharmaceutical companies. The total value of these specific reported holdings is approximately $24.3 million. Key positions include:
- Personalis Inc.: 14,044,943 shares valued at $89,466,287 (Note: Value column appears to be misaligned in source text; based on share count and typical pricing, this is the largest position by share count, though the dollar value listed in the text for this row is $89,466,287 which seems inconsistent with the share count of 14M unless price is ~$6.40. However, strictly reading the "Value" column for Personalis shows $89,466,287. Wait, re-reading the raw text: "89,466,287 14,044,943". Column 4 is Value, Column 5 is Shares. So Value is $89,466,287 and Shares are 14,044,943. This implies a price of ~$6.38. This is the largest single position by value in this list).
- Aktis Oncology Inc.: 952,844 shares valued at $17,046,379.
- Alector Inc.: 3,545,719 shares valued at $7,623,297.
- Moderna Inc.: 2,308,190 shares valued at $117,256,052 (Note: Text shows "117,256,052 2,308,190". Value is $117M, Shares 2.3M. Price ~$50.80).
- Eikon Therapeutics Inc.: 1,666,666 shares valued at $17,633,326.
Correction on Total Value Calculation based on text alignment: The text format is "Value Shares". - Aktis: $17,046,379 - Alector: $7,623,297 - Carisma: $47,880 (Value) / 1,473,240 (Shares) -> This seems inverted or a typo in source. Usually Value > Shares for small caps. Let's re-read carefully: "47,880 1,473,240". If Value is 47k and Shares 1.4M, price is $0.03. If Value is 1.4M and Shares 47k, price is $31. Given the other entries, the first number is likely Value. - Moderna: $117,256,052 - Personalis: $89,466,287 - Eikon: $17,633,326 - Entrada: $21,955,872 - Evaxion: $4,516,549 - Kymira: $64,313,623 - Neuphoria: $40,810 - Sutro: $6,784,263 - Tuhura: $34,807 - Viridian: $1,827,178 - Xilio: $891,309
Total Reported Value of Listed Positions: Approximately $343.5 million (Sum of Column 4 values).
Material Changes
The filing text provided does not include comparative data from the prior quarter (December 31, 2025). Therefore, material changes in position size or value versus the prior period cannot be determined from this document alone.
Guidance, Outlook, and Risks
This Form 13F filing does not contain management commentary, financial guidance, or risk factors regarding Merck's own business operations. It strictly reports investment holdings. All listed positions are held with Sole Discretion (Column 7: "SOLE").
Investor Verification Checklist
- Verify the alignment of "Value" and "Shares" columns for Carisma Therapeutics, Neuphoria Therapeutics, and Tuhura Biosciences, as the values appear unusually low relative to share counts in the raw text.
- Confirm the total portfolio value of Merck's 13F holdings against the company's total assets to understand the significance of these specific biotech investments.
- Check the prior quarter's 13F filing to determine if these positions were new purchases, sales, or held steady.
- Note that the filing date (March 31, 2026) is in the future relative to the current real-time date; verify if this is a hypothetical scenario or a data entry error in the source.